- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 186972, 9 pages
Long-Term Nitric Oxide Exposure Enhances Lung Cancer Cell Migration
Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences and Cell-based Drug and Health Product Development Research Unit, Chulalongkorn University, Bangkok, Thailand
Received 25 April 2013; Revised 27 June 2013; Accepted 28 June 2013
Academic Editor: Silvia Gregori
Copyright © 2013 Arpasinee Sanuphan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000.
- G. Manda, M. T. Nechifor, and T.-M. Neagu, “Reactive oxygen species, cancer and anti-cancer therapies,” Current Chemical Biology, vol. 3, no. 1, pp. 22–46, 2009.
- A. Keibel, V. Singh, and M. C. Sharma, “Inflammation, microenvironment, and the immune system in cancer progression,” Current Pharmaceutical Design, vol. 15, no. 17, pp. 1949–1955, 2009.
- P. K. Lala and C. Chakraborty, “Role of nitric oxide in carcinogenesis and tumour progression,” Lancet Oncology, vol. 2, no. 3, pp. 149–156, 2001.
- F. Masri, “Role of nitric oxide and its metabolites as potential markers in lung cancer,” Annals of Thoracic Medicine, vol. 5, no. 3, pp. 123–127, 2010.
- F. A. Masri, S. A. A. Comhair, T. Koeck et al., “Abnormalities in nitric oxide and its derivatives in lung cancer,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 5, pp. 597–605, 2005.
- H. Esme, M. Cemek, M. Sezer et al., “High levels of oxidative stress in patients with advanced lung cancer,” Respirology, vol. 13, no. 1, pp. 112–116, 2008.
- D. H. Geho, R. W. Bandle, T. Clair, and L. A. Liotta, “Physiological mechanisms of tumor-cell invasion and migration,” Physiology, vol. 20, no. 3, pp. 194–200, 2005.
- L. A. Mina and G. W. Sledge Jr., “Rethinking the metastatic cascade as a therapeutic target,” Nature Reviews Clinical Oncology, vol. 8, no. 6, pp. 325–332, 2011.
- M. Parri and P. Chiarugi, “Rac and Rho GTPases in cancer cell motility control,” Cell Communication and Signaling, vol. 8, no. 23, pp. 1–14, 2010.
- C. D. Nobes and A. Hall, “Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia,” Cell, vol. 81, no. 1, pp. 53–62, 1995.
- B. Serrels, A. Serrels, V. G. Brunton et al., “Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex,” Nature Cell Biology, vol. 9, no. 9, pp. 1046–1056, 2007.
- L. A. Cary, J. F. Chang, and J.-L. Guan, “Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn,” Journal of Cell Science, vol. 109, no. 7, pp. 1787–1794, 1996.
- S. K. Mitra, D. A. Hanson, and D. D. Schlaepfer, “Focal adhesion kinase: in command and control of cell motility,” Nature Reviews Molecular Cell Biology, vol. 6, no. 1, pp. 56–68, 2005.
- W. E. Allen, G. E. Jones, J. W. Pollard, and A. J. Ridley, “Rho, Rac and Cdc42 regulate actin organization and cell adhesion in macrophages,” Journal of Cell Science, vol. 110, no. 6, pp. 707–720, 1997.
- K. Kaibuchi, S. Kuroda, and M. Amano, “Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells,” Annual Review of Biochemistry, vol. 68, pp. 459–486, 1999.
- T. M. Williams and M. P. Lisanti, “Caveolin-1 in oncogenic transformation, cancer, and metastasis,” American Journal of Physiology—Cell Physiology, vol. 288, no. 3, pp. C494–C506, 2005.
- P. Chanvorachote, U. Nimmannit, Y. Lu, S. Talbott, B.-H. Jiang, and Y. Rojanasakul, “Nitric oxide regulates lung carcinoma cell anoikis through inhibition of ubiquitin-proteasomal degradation of caveolin-1,” Journal of Biological Chemistry, vol. 284, no. 41, pp. 28476–28484, 2009.
- S. Luanpitpong, S. J. Talbott, Y. Rojanasakul et al., “Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1,” Journal of Biological Chemistry, vol. 285, no. 50, pp. 38832–38840, 2010.
- P. Rungtabnapa, U. Nimmannit, H. Halim, Y. Rojanasakul, and P. Chanvorachote, “Hydrogen peroxide inhibits non-small cell lung cancer cell anoikis through the inhibition of caveolin-1 degradation,” American Journal of Physiology—Cell Physiology, vol. 300, no. 2, pp. C235–C245, 2011.
- K. Pongjit and P. Chanvorachote, “Caveolin-1 sensitizes cisplatin-induced lung cancer cell apoptosis via superoxide anion-dependent mechanism,” Molecular and Cellular Biochemistry, vol. 358, no. 1-2, pp. 365–373, 2011.
- P. Chunhacha, V. Pongrakhananon, Y. Rojanasakul, and P. Chanvorachote, “Caveolin-1 regulates Mcl-1 stability and anoikis in lung carcinoma cells,” American Journal of Physiology—Cell Physiology, vol. 302, no. 9, pp. C1284–C1292, 2012.
- T. Songserm, V. Pongrakhananon, and P. Chanvorachote, “Sub-toxic cisplatin mediates anoikis resistance through hydrogen peroxide-induced caveolin-1 up-regulation in non-small cell lung cancer cells,” Anticancer Research, vol. 32, no. 5, pp. 1659–1669, 2012.
- H. Halim, S. Luanpitpong, and P. Chanvorachote, “Acquisition of anoikis resistance up-regulates caveolin-1 expression in human non-small cell lung cancer cells,” Anticancer Research, vol. 32, no. 5, pp. 1649–1658, 2012.
- W. Suchaoin and P. Chanvorachote, “Caveolin-1 attenuates hydrogen peroxide-induced oxidative damage to lung carcinoma cells,” Anticancer Research, vol. 32, no. 2, pp. 483–490, 2012.
- P. Chunhacha and P. Chanvorachote, “Roles of caveolin-1 on anoikis resistance in non small cell lung cancer,” International Journal of Physiology, Pathophysiology and Pharmacology, vol. 4, no. 3, pp. 149–155, 2012.
- C.-C. Ho, P.-H. Huang, H.-Y. Huang, Y.-H. Chen, P.-C. Yang, and S.-M. Hsu, “Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation,” American Journal of Pathology, vol. 161, no. 5, pp. 1647–1656, 2002.
- F. Sotgia, U. E. Martinez-Outschoorn, A. Howell, R. G. Pestell, S. Pavlides, and M. P. Lisanti, “Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms,” Annual Review of Pathology: Mechanisms of Disease, vol. 7, pp. 423–467, 2012.
- V. P. Terranova, E. S. Hujanen, D. M. Loeb, G. R. Martin, L. Thornburg, and V. Glushko, “Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 2, pp. 465–469, 1986.
- D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005.
- M. Paesmans, J. P. Sculier, P. Libert et al., “Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients,” Journal of Clinical Oncology, vol. 13, no. 5, pp. 1221–1230, 1995.
- S. Moncada and A. Higgs, “The L-arginine-nitric oxide pathway,” The New England Journal of Medicine, vol. 329, no. 27, pp. 2002–2012, 1993.
- R. Sarkar, E. G. Meinberg, J. C. Stanley, R. D. Gordon, and R. C. Webb, “Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells,” Circulation Research, vol. 78, no. 2, pp. 225–230, 1996.
- A. Chen, S. M. Kumar, C. L. Sahley, and K. J. Muller, “Nitric oxide influences injury-induced microglial migration and accumulation in the leech CNS,” Journal of Neuroscience, vol. 20, no. 3, pp. 1036–1043, 2000.
- A. Dhar, J. M. Brindley, C. Stark, M. L. Citro, L. K. Keefer, and N. H. Colburn, “Nitric oxide does not mediate but inhibits transformation and tumor phenotype,” Molecular Cancer Therapeutics, vol. 2, no. 12, pp. 1285–1293, 2003.
- D. Fukumura, S. Kashiwagi, and R. K. Jain, “The role of nitric oxide in tumour progression,” Nature Reviews Cancer, vol. 6, no. 7, pp. 521–534, 2006.
- J. R. Hickok, S. Sahni, Y. Mikhed, M. G. Bonini, and D. D. Thomas, “Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 (NDRG1) expression: role of chelatable iron,” Journal of Biological Chemistry, vol. 286, no. 48, pp. 41413–41424, 2011.
- C. Polytarchou, M. Hatziapostolou, E. Poimenidi et al., “Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase β/ζ,” International Journal of Cancer, vol. 124, no. 8, pp. 1785–1793, 2009.
- J. Turečková, M. Vojtěchová, M. Krausová, E. Šloncová, and V. Korínek, “Focal adhesion kinase functions as an akt downstream target in migration of colorectal cancer cells,” Translational Oncology, vol. 2, no. 4, pp. 281–290, 2009.